Cases & Deals

  • Home
  • Practices
  • NGM develops global patent portfolio for beta-klotho antibodies

Share

NGM develops global patent portfolio for beta-klotho antibodies

January 2016

Client(s) NGM Biopharmaceuticals, Inc.

Jones Day represents NGM Biopharmaceuticals, Inc. in the development of a global patent portfolio for antibodies to beta-klotho for the treatment of diabetes and other metabolic disorders.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.